These include allergen modifications, altered therapeutic formulations, optimization of the vaccine introduction route, innovative B-cell-focused approach by inducing IgE-competitive IgG response, different choices of vaccine carriers and adjuvants, and combined treatment of the allergy using both AIT and pharmacologic/biologic agent [65]. This evidence concerns the gene IGHE and allergic disease.